Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACELRX PHARMACEUTICALS, INC.

(ACRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AcelRx Pharmaceuticals : Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event

08/26/2021 | 08:31am EST

HAYWARD, Calif., Aug. 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation on the effects of administering sufentanil sublingual tablet 30 mcg (SST) at Miami Cosmetic Surgery held at the Miami Beach Convention Center in Miami Beach, Florida from August 25-27, 2021.

Hisham Seify, MD, PhD, FACS will present data on the administration of SST and its effect on reducing post-operative recovery time and opioid use in the outpatient plastic surgery setting in patients undergoing "awake" procedures not under general anesthesia. This new data from Dr. Seify's study is distinct from the study previously performed by Dr. Seify in patients under general anesthesia, which was presented in May 2021. Dr. Seify is a board-certified plastic surgeon and the past-president of the Orange County Society of Plastic Surgeons. Dr. Seify is a paid consultant for AcelRx but was not compensated for this study.

Session Title: Surgical Complications, Even the Best Laid Plans…
Presentation Title: The Effect of the Administration of Sublingual Sufentanil on Reducing Post-Operative Recovery Time and Opioid Use in the Outpatient Plastic Surgery Setting
Session Date: Friday, August 27, 2021
Session Time: 11:30 AM1:00 PM EDT

About DSUVIA (sufentanil sublingual tablet), 30 mcg
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with intravenous (IV) administration. DSUVIA is a single-strength solid dosage form administered sublingually via a single-dose applicator (SDA) by healthcare professionals. Sufentanil is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia. The sufentanil pharmacokinetic profile when delivered sublingually avoids the high peak plasma levels and short duration of action observed with IV administration. The European Commission approved DZUVEO for marketing in Europe and it will be commercialized by AcelRx's European partner, Aguettant.

This release is intended for investors only. For more information, including important safety information and black box warning for DSUVIA, please visit www.DSUVIA.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.  AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and several product candidates.  The product candidates include Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S. being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings, and two pre-filled, ready-to-use syringes of ephedrine and phenylephrine licensed for the U.S. from Aguettant. DZUVEO and Zalviso are both approved products in Europe.

For additional information about AcelRx, please visit www.acelrx.com.

AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)

 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/presentation-on-the-effect-of-the-administration-of-sufentanil-sublingual-tablet-on-reducing-post-operative-recovery-time-and-opioid-use-in-plastic-surgery-at-the-annual-miami-cosmetic-surgery-event-301363317.html

SOURCE AcelRx Pharmaceuticals, Inc.


ę PRNewswire 2021
All news about ACELRX PHARMACEUTICALS, INC.
12/03ACELRX PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing..
AQ
12/01Cantor Fitzgerald Lowers Price Target for AcelRx Pharmaceuticals to $4 From $9, Maintai..
MT
11/23ACELRX PHARMACEUTICALS : Announces the Appointment of Jill Broadfoot to its Board of Direc..
PU
11/23ACELRX PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
11/23AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Dire..
PR
11/23AcelRx Pharmaceuticals, Inc. Appoints Jill Broadfoot to Board of Directors
CI
11/15ACELRX PHARMACEUTICALS : Q3 Earnings Snapshot
AQ
11/15ACELRX PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/15ACELRX PHARMACEUTICALS : to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Fin..
PU
11/15ACELRX PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition..
AQ
More news
Analyst Recommendations on ACELRX PHARMACEUTICALS, INC.
More recommendations